VCYT

43.60

7.44% 3.02

Pre-mercato: 44.00 0.40 +0.92%

Veracyte Inc (VCYT)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$40.58

Aprire:

$41.14

Volume 24 ore:

663.51K

Relative Volume:

0.89

Capitalizzazione di mercato:

$3.29B

Reddito:

$399.58M

Utile/perdita netta:

$-54.04M

Rapporto P/E:

-58.13

EPS:

-0.75

Flusso di cassa netto:

$40.13M

1 W Prestazione:

+6.19%

1M Prestazione:

+6.63%

6M Prestazione:

+88.09%

1 anno Prestazione:

+70.78%

Intervallo 1D:

$41.13

$43.68

Intervallo di 1 settimana:

$40.29

$43.68

Portata 52W:

$18.61

$46.00

Veracyte Inc Stock (VCYT) Company Profile

Nome

Veracyte Inc

Settore

Healthcare (1176)

Industria

Diagnostics & Research (59)

Telefono

(650) 243-6300

Indirizzo

6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA

Dipendente

Cinguettio

@veracyte

Prossima data di guadagno

2024-11-06

Ultimi documenti SEC

VCYT's Discussions on Twitter

Confronta VCYT con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
VCYT Veracyte Inc	43.60	3.29B	399.58M	-54.04M	40.13M	-0.75
TMO Thermo Fisher Scientific Inc	573.06	219.20B	42.37B	6.14B	7.78B	15.95
DHR Danaher Corp	244.11	176.31B	23.74B	3.89B	4.98B	5.24
A Agilent Technologies Inc	152.57	43.57B	6.51B	1.29B	1.37B	4.42
IQV Iqvia Holdings Inc	205.69	37.33B	15.32B	1.41B	1.96B	7.62
IDXX Idexx Laboratories Inc	427.33	34.99B	3.84B	866.24M	792.60M	10.37

Veracyte Inc Stock (VCYT) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-12-05	Downgrade	Goldman	Buy → Neutral
2024-11-15	Iniziato	Wolfe Research	Outperform
2024-10-16	Iniziato	UBS	Buy
2024-10-10	Iniziato	Guggenheim	Buy
2024-02-23	Reiterato	Needham	Buy
2023-01-18	Downgrade	Raymond James	Outperform → Mkt Perform
2023-01-05	Iniziato	Scotiabank	Sector Outperform
2022-01-07	Iniziato	Stephens	Overweight
2021-11-18	Ripresa	Goldman	Buy
2021-06-15	Iniziato	Raymond James	Outperform
2021-02-18	Ripresa	Needham	Buy
2021-01-28	Iniziato	Truist	Buy
2020-11-10	Iniziato	KeyBanc Capital Markets	Sector Weight
2020-09-09	Iniziato	Morgan Stanley	Underweight
2019-07-31	Iniziato	Lake Street	Buy
2019-07-02	Iniziato	Needham	Buy
2018-11-29	Downgrade	Janney	Buy → Neutral
2018-10-31	Aggiornamento	Janney	Neutral → Buy
2017-11-07	Downgrade	Janney	Buy → Neutral
2017-11-07	Downgrade	Piper Jaffray	Overweight → Neutral
2017-08-31	Ripresa	BTIG Research	Buy
2016-11-14	Ripresa	Leerink Partners	Outperform
2015-12-18	Iniziato	Cantor Fitzgerald	Buy
2015-06-11	Reiterato	Leerink Partners	Outperform
2013-11-26	Iniziato	William Blair	Outperform

Mostra tutto

Veracyte Inc Borsa (VCYT) Ultime notizie

Jan 21, 2025

AMI Asset Management Corp Lowers Stake in Veracyte, Inc. (NASDAQ:VCYT) - MarketBeat

Jan 21, 2025

Jan 19, 2025

Avanza Fonder AB Makes New $1.38 Million Investment in Veracyte, Inc. (NASDAQ:VCYT) - MarketBeat

Jan 19, 2025

Jan 18, 2025

Harbor Capital Advisors Inc. Reduces Position in Veracyte, Inc. (NASDAQ:VCYT) - MarketBeat

Jan 13, 2025

Jan 12, 2025

Catherine Wood's Strategic Reduction in Veracyte Inc Shares - GuruFocus.com

Jan 12, 2025

Jan 10, 2025

Diversified Trust Co Cuts Stake in Veracyte, Inc. (NASDAQ:VCYT) - MarketBeat

Jan 10, 2025

Jan 09, 2025

Veracyte, Inc. (NASDAQ:VCYT) Has Found A Path To Profitability - Yahoo Finance

Jan 09, 2025

Jan 08, 2025

Veracyte Gains 44% in a Year: What's Driving the Stock? - MSN

Jan 08, 2025

Jan 07, 2025

The Zacks Rank Explained: How to Find Strong Buy Medical Stocks - Yahoo Finance

Jan 07, 2025

Jan 06, 2025

Veracyte director Karin Eastham sells shares worth $403,005 By Investing.com - Investing.com Australia

Jan 06, 2025

Insider Selling: Veracyte, Inc. (NASDAQ:VCYT) Director Sells 10,000 Shares of Stock - MarketBeat

Jan 06, 2025

Veracyte director Karin Eastham sells shares worth $403,005 - Investing.com

Jan 06, 2025